dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
Which diabetes groups lead or lag on COVID-19 shots? See dQ&A’s panel results from March 2021 and uncover barriers to higher coverage.
5,700 dQ&A community members share where they were diagnosed, first symptoms, and emotions—highlighting key differences between type 1 and type 2 journeys.
Part 2 of dQ&A’s CGM series digs into adoption barriers and the Ambulatory Glucose Profile, which can help people make sense of the data CGMs provide.
This study examines how income affects diabetes outcomes, finding lower-income adults with type 2 diabetes face higher rates of complications and depression.
Concerns about family or friends getting COVID-19 and about getting COVID-19 oneself increased, as case numbers rose nationally over the summer.
We asked patients about using—and endocrinologists about prescribing—a connected insulin pen.
Our fifth COVID-19 impact survey shows Black & Latino adults with diabetes faced more COVID-19 cases, insulin rationing, and financial strain.
Our research with the ADA shows that people with diabetes are much worse off under the COVID-19 pandemic, compared to the nation as a whole.
